汉丹肝乐抗大鼠免疫性肝纤维化的实验研究  

Experimental Study on Anti-Immunologic Liver Fibrosis Effect of Handan Ganle

作　　者：张慧娜[1] 黄能慧[1] 李诚秀[1] 李玲[1] 程明亮[2] 

机构地区：[1]贵阳医学院药理学教研室 [2]贵阳医学院附属医院传染科

出　　处：《中国中西医结合杂志》2001年第S1期77-79,共3页Chinese Journal of Integrated Traditional and Western Medicine

基　　金：贵州省"九五"攻关课题部分内容

摘　　要：目的:探讨汉丹肝乐对大鼠免疫性肝纤维化的治疗作用。方法:腹腔注射猪血清复制大鼠免疫性肝纤维化模型后给予汉丹肝乐低、中、高3个剂量,持续12周,并进行相应指标检测。结果:汉丹肝乐中、高剂量能减轻模型大鼠的肝组织学病变,增加尿羟脯氨酸排出量,降低血清谷丙转氨酶(ALT)、碱性磷酸酶(AKP)、丙二醛(MDA)及肝脏 MDA 水平、胶原蛋白含量。免疫组化染色显示,中、高剂量组大鼠肝脏Ⅰ型胶原阳性着色少而浅。电镜观察显示,汉丹肝乐组大鼠超微结构破坏轻。结论:汉丹肝乐可减轻猪血清所诱导的大鼠免疫性肝纤维化。Objective: To observe the therapeutic effect on hepatic fibrosis of chronic hepatitis B by Chinese medicine Handan Ganle capsule (HDGLC).Methods: A total of 104 patients with chronic hepatitis B has been treated by HDGLC for 6 months, liver fibrosis indexes and the serum biochemical indexes were detected before treatment, during the curative period and by the end of treatment. Hepatic biopsy was performed before or after the treatment.Results: The improvement rate of clinical symptoms was 79.0%-90.6%, and the recovery rate of ALT was 72.6%, serum fibrosis indexes such as HA, type Ⅳ collagen and LN were significantly decreased along with the extending course of disease ( P <0.05). The pathohistological score of liver was decreased from 7.82±6.22 before treatment to 5.16±3.75 after treatment ( P <0.05) and the score of hepatic fibrosis was decreased from 7.49±5.45 before treatment to 5.16±4.26 after treatment ( P <0.05).Conclusion: HDGLC has remarkable therapeutic and reversing effect on chronic hepatitis B induced hepatic fibrosis.

关 键 词：汉丹肝乐 免疫性肝纤维化 羟脯氨酸 Ⅰ型胶原 脂质过氧化 

分 类 号：R285.5[医药卫生—中药学]